QCM
SPRY icon

Quantinno Capital Management’s ARS Pharmaceuticals SPRY Stock Holding History

Quantinno Capital Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$997K Buy
124,429
+23,017
+23% +$198K ﹤0.01% 2563
2026
Q1 		$814K Buy
101,412
+48,299
+91% +$463K ﹤0.01% 2337
2025
Q4 		$619K Buy
53,113
+12,641
+31% +$123K ﹤0.01% 2205
2025
Q3 		$407K Buy
+40,472
New +$581K ﹤0.01% 2198

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Quantinno Capital Management's SPRY Position: Q2 2026 in Review

Quantinno Capital Management increased its ARS Pharmaceuticals (SPRY) stake by 23% in Q2 2026, buying an estimated $198K and bringing the position to 124,429 shares worth $997K. The position accounts for ﹤0.01% of the portfolio, ranked #2563.

Quantinno Capital Management first reported a position in SPRY in Q3 2025 and has held it in 4 quarters since. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Quantinno Capital Management held 124,429 shares of ARS Pharmaceuticals worth $997K as of Q2 2026.
  • Quantinno Capital Management bought 23,017 ARS Pharmaceuticals shares in Q2 2026, an estimated $198K.
  • ARS Pharmaceuticals made up ﹤0.01% of Quantinno Capital Management's portfolio in Q2 2026, its #2563 holding.
  • Quantinno Capital Management first reported a position in ARS Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Quantinno Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.